Second HealthTech call
25 January 2023
Leading innovation for the benefit of patients
A new funding opportunity to companies, research and healthcare organisations looking to work together to co-develop healthtech products or services at prototype stage and validate these solutions at a clinical level.
Based on the strength of the first Joint Call HealthTech, the Ministry of the Economy, the National Research Fund and Luxinnovation join forces again to further build the collaboration culture between companies, research and healthcare organisations. This includes matching HealthTech products or services at prototype stage with research and healthcare expertise to co-develop and validate these solutions at a clinical level for the benefit of patients and deliver leading innovation.
Call open from 1 February 2023 to 31 March 2023.
Innovative digital health solutions
The overall goal of this new joint healthtech call is the development and validation of innovative digital health solutions benefiting the national healthcare (patients, healthcare professionals, payers), research and innovation ecosystems.
The joint call intends to incentivise collaborative R&D projects for improvement of health and care delivery focused on medical evidence, harnessing the opportunities of digital health (mHealth, telemonitoring, AI, personalised medicine…) in order to enable a patient-centred healthcare.
It also aims to provide a financial incentive to consortia who have a specific digital product or service at prototype stage for which they wish to demonstrate its relevance and benefit for human health and society.
Topic of the call
Proposed solutions through this call should include the use of digital tools to improve prevention, diagnosis, monitoring or treatment of health conditions to improve public health or to increase patient autonomy, such as at home or in a care home environment.
Products to be developed through this call must be innovative digital health solutions for human use that (1) are already at prototype stage and that can meet at least one of (2a) or (2b):
- (2a) are or will be regulated by the medical device regulation (MDR)2 or in-vitro medical device regulation (IVDR)3. (Examples: digital medical devices, digital health applications, connected medical devices)
- (2b) that will apply innovative data processing or analysis techniques on real world data from healthcare or care environments to prove a societal impact.
In line with national priorities seeking to develop personalised medicine further, and in line with strategic intentions to build a data innovation service platform, consortia will have to align to the following approaches:
- Innovative clinical investigations: centred on taking the current state of the art in clinical trials and refining their design and implementation through innovative means such as digital tools, smart wearables and sensors, electronic medical record analysis, and other precision medicine approaches. These clinical trials should bring added value to patients.
- Multifactorial intervention strategies: focused on designing and testing interventions that are not molecular in nature, for example through lifestyle and digital means. The goal is to improve health through innovative, participatory, and personalised intervention strategies, resulting in health-associated impact through interdisciplinary research.
HealthTech call: information sessions
A webinar series presenting the objectives of the Joint Call HealthTech as well as the process of preparing applications, is organised. First session will be held on 2023, February 1 and will followed by a Q&A session.
10 selected Research Luxembourg results – August 2023Are our European rivers in good health? Luxembourg Institute of Science and Technology (LIST) Over the past few decades, life…
10 selected Research Luxembourg results – July 2023An antibody to tackle skin cancer? Laboratoire National de Santé (LNS), Luxembourg Centre for Systems Biomedicine (LCSB), Luxembourg Institute of…
A new breakthrough in cancer treatmentAn international team of researchers, including Prof. Michel Mittelbronn, Head of the National Centre of Pathology at the Laboratoire Nationale…
SciLux podcast – Catherine Sedrani, microbiologistCould we find another link between what we eat and the diseases we develop? A Gut-On-A-Chip model Dr Catherine Sedrani…
10 selected Research Luxembourg results – June 2023When artificial intelligence explores space Interdisciplinary Centre for Security, Reliability and Trust (SnT) – University of Luxembourg AI is increasingly…
Cutting-edge research in Luxembourg: A Drug Slows Down Leukaemia Progression by Blocking Cancer-Causing GenesResearchers from the Luxembourg Institute of Health reveal the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation…
10 selected Research Luxembourg results – May 2023A blood test for effective diagnosis of Parkinson’s disease NCER-PD (LCSB, LIH, IBBL, CHL, LNS) Is it now possible to…
10 selected Research Luxembourg results – April 2023Can artificial intelligence guide our artistic choices? University of Luxembourg The answer obviously depends on our expectations! AI could, for…
Unlocking breakthroughs: Japan-Luxembourg collaboration unveils key discoveries for diagnosing neurodegenerative diseasesAn international team consisting of researchers from Japan and Luxembourg show for the first time that pathological forms of the…
Prof. Tkatchenko receives an ERC grant for drug development with AIThe physicist Prof. Alexandre Tkatchenko of the University of Luxembourg, has received a “Proof of Concept” Grant from the European…